FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3210054410> ?p ?o ?g. }

• W3210054410 endingPage "e384" @default.
• W3210054410 startingPage "e384" @default.
• W3210054410 abstract "Purpose/Objective(s)To evaluate the value of locoregional radiation therapy (LRRT) in de novo metastatic nasopharyngeal carcinoma (mNPC) and identify suitable candidates for additional LRRT after palliative chemotherapy (PCT).Materials/MethodsPatients with de novo mNPC and received platinum-based chemotherapy for a minimum of 4 cycles with or without definitive LRRT via intensity-modulated radiation therapy (IMRT) were all candidates for this study.ResultsA total of 168 patients were included for this analysis. Additional LRRT was associated with significantly longer median OS (69.5 months vs. 17.8 months, P < 0.001) when compared with PCT alone. However, this additional benefit of LRRT was only reflected in patients with oligometastatic diseases (90.8 months vs. 17 months, P < 0.001), but not for those with polymetastatic disease (P = 0.86).ConclusionAdditional LRRT after PCT may only improve OS for oligometastatic patients. For patients with polymetastatic disease, intensive systemic treatment such as the combination of immunotherapy and adequate PCT might be necessary. To evaluate the value of locoregional radiation therapy (LRRT) in de novo metastatic nasopharyngeal carcinoma (mNPC) and identify suitable candidates for additional LRRT after palliative chemotherapy (PCT). Patients with de novo mNPC and received platinum-based chemotherapy for a minimum of 4 cycles with or without definitive LRRT via intensity-modulated radiation therapy (IMRT) were all candidates for this study. A total of 168 patients were included for this analysis. Additional LRRT was associated with significantly longer median OS (69.5 months vs. 17.8 months, P < 0.001) when compared with PCT alone. However, this additional benefit of LRRT was only reflected in patients with oligometastatic diseases (90.8 months vs. 17 months, P < 0.001), but not for those with polymetastatic disease (P = 0.86). Additional LRRT after PCT may only improve OS for oligometastatic patients. For patients with polymetastatic disease, intensive systemic treatment such as the combination of immunotherapy and adequate PCT might be necessary." @default.
• W3210054410 created "2021-11-08" @default.
• W3210054410 creator A5001574076 @default.
• W3210054410 creator A5013732820 @default.
• W3210054410 creator A5013972195 @default.
• W3210054410 creator A5015488490 @default.
• W3210054410 creator A5024468864 @default.
• W3210054410 creator A5035202459 @default.
• W3210054410 creator A5044071076 @default.
• W3210054410 creator A5051537826 @default.
• W3210054410 creator A5051544481 @default.
• W3210054410 creator A5068690142 @default.
• W3210054410 creator A5073395498 @default.
• W3210054410 creator A5087454111 @default.
• W3210054410 date "2021-11-01" @default.
• W3210054410 modified "2023-09-26" @default.
• W3210054410 title "Identifying the Optimal Candidates for the Best Utilization of Locoregional Radiation Therapy in Patients With De Novo Metastatic Nasopharyngeal Carcinoma" @default.
• W3210054410 doi "https://doi.org/10.1016/j.ijrobp.2021.07.1124" @default.
• W3210054410 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34701326" @default.
• W3210054410 hasPublicationYear "2021" @default.
• W3210054410 type Work @default.
• W3210054410 sameAs 3210054410 @default.
• W3210054410 citedByCount "0" @default.
• W3210054410 crossrefType "journal-article" @default.
• W3210054410 hasAuthorship W3210054410A5001574076 @default.
• W3210054410 hasAuthorship W3210054410A5013732820 @default.
• W3210054410 hasAuthorship W3210054410A5013972195 @default.
• W3210054410 hasAuthorship W3210054410A5015488490 @default.
• W3210054410 hasAuthorship W3210054410A5024468864 @default.
• W3210054410 hasAuthorship W3210054410A5035202459 @default.
• W3210054410 hasAuthorship W3210054410A5044071076 @default.
• W3210054410 hasAuthorship W3210054410A5051537826 @default.
• W3210054410 hasAuthorship W3210054410A5051544481 @default.
• W3210054410 hasAuthorship W3210054410A5068690142 @default.
• W3210054410 hasAuthorship W3210054410A5073395498 @default.
• W3210054410 hasAuthorship W3210054410A5087454111 @default.
• W3210054410 hasBestOaLocation W32100544101 @default.
• W3210054410 hasConcept C126322002 @default.
• W3210054410 hasConcept C143998085 @default.
• W3210054410 hasConcept C2776694085 @default.
• W3210054410 hasConcept C2777546739 @default.
• W3210054410 hasConcept C2778997737 @default.
• W3210054410 hasConcept C509974204 @default.
• W3210054410 hasConcept C71924100 @default.
• W3210054410 hasConceptScore W3210054410C126322002 @default.
• W3210054410 hasConceptScore W3210054410C143998085 @default.
• W3210054410 hasConceptScore W3210054410C2776694085 @default.
• W3210054410 hasConceptScore W3210054410C2777546739 @default.
• W3210054410 hasConceptScore W3210054410C2778997737 @default.
• W3210054410 hasConceptScore W3210054410C509974204 @default.
• W3210054410 hasConceptScore W3210054410C71924100 @default.
• W3210054410 hasIssue "3" @default.
• W3210054410 hasLocation W32100544101 @default.
• W3210054410 hasLocation W32100544102 @default.
• W3210054410 hasOpenAccess W3210054410 @default.
• W3210054410 hasPrimaryLocation W32100544101 @default.
• W3210054410 hasRelatedWork W2358752229 @default.
• W3210054410 hasRelatedWork W2359948402 @default.
• W3210054410 hasRelatedWork W2372838325 @default.
• W3210054410 hasRelatedWork W2375776487 @default.
• W3210054410 hasRelatedWork W2379282113 @default.
• W3210054410 hasRelatedWork W2379380436 @default.
• W3210054410 hasRelatedWork W2384200964 @default.
• W3210054410 hasRelatedWork W2387690194 @default.
• W3210054410 hasRelatedWork W2392262560 @default.
• W3210054410 hasRelatedWork W2393154103 @default.
• W3210054410 hasVolume "111" @default.
• W3210054410 isParatext "false" @default.
• W3210054410 isRetracted "false" @default.
• W3210054410 magId "3210054410" @default.
• W3210054410 workType "article" @default.